Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection drug SHR-A1811 and others approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that recently, the company and its subsidiaries Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Pharmaceutical Co., Ltd. have received the approval and issuance of the "Drug Clinical Trial Approval Notice" by the National Medical Products Administration (referred to as the "NMPA") for injection SHR-A1811, Atezolizumab injection, and Famicitinib Capsules. They will soon begin clinical trials. Specifically, the clinical trial will be an open, multicenter phase b/ study on the use of injection SHR-A1811 in combination with antitumor drugs for the treatment of solid tumors.